Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma

BACKGROUND: In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS), objective response rate (ORR), and overall survival (OS) versus everolimus in patients with advanced renal cell carcinoma (RCC), after prior antiangiogenic therapy. METHODS: Outcomes were evaluated for su...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Br J Cancer
Glavni autori: Powles, Thomas, Motzer, Robert J., Escudier, Bernard, Pal, Sumanta, Kollmannsberger, Christian, Pikiel, Joanna, Gurney, Howard, Rha, Sun Young, Park, Se Hoon, Geertsen, Poul F., Gross-Goupil, Marine, Grande, Enrique, Suarez, Cristina, Markby, David W., Arroyo, Alan, Dean, Mark, Choueiri, Toni K., George, Daniel
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2018
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6173766/
https://ncbi.nlm.nih.gov/pubmed/30197417
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0164-0
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items